
Quarterly report 2022-Q3
added 11-14-2022
CASI Pharmaceuticals Net Debt 2011-2026 | CASI
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt CASI Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -36.5 M | -55.8 M | -51.4 M | -82.7 M | -42 M | -25.6 M | -3.67 M | -9.28 M | -15.1 M | -7.95 M | -1.08 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -1.08 M | -82.7 M | -30.1 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
Aptorum Group Limited
APM
|
-2.77 M | $ 1.06 | -1.85 % | $ 5.78 M | ||
|
Adagene
ADAG
|
-71 M | $ 1.72 | 4.24 % | $ 96.8 M | ||
|
Ascendis Pharma A/S
ASND
|
-195 M | $ 203.22 | -2.65 % | $ 5 B | ||
|
Alterity Therapeutics Limited
ATHE
|
-34.7 M | $ 3.5 | 5.11 % | $ 8.42 B | ||
|
Arrowhead Pharmaceuticals
ARWR
|
-115 M | $ 64.63 | -0.57 % | $ 8.64 B | ||
|
Autolus Therapeutics plc
AUTL
|
-187 M | $ 1.83 | -4.45 % | $ 467 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
Albireo Pharma
ALBO
|
-239 M | - | -0.23 % | $ 916 M | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
Alpine Immune Sciences
ALPN
|
-63.9 M | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-12 M | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
-56.5 M | - | - | $ 10.1 M | ||
|
Biogen
BIIB
|
4.01 B | $ 187.5 | 0.81 % | $ 27.3 B | ||
|
Aravive
ARAV
|
-49.6 M | - | -13.39 % | $ 1.45 M | ||
|
Arena Pharmaceuticals
ARNA
|
-25.4 M | - | -6.81 % | $ 3.04 B | ||
|
Athersys
ATHX
|
-27.6 M | - | 3.77 % | $ 22.4 M | ||
|
Avenue Therapeutics
ATXI
|
-3.13 K | - | -52.27 % | $ 4.45 M | ||
|
AIkido Pharma
AIKI
|
-1.04 M | - | 1.93 % | $ 17.4 M | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
BioVie
BIVI
|
-17.2 M | $ 1.27 | -2.31 % | $ 1.88 M | ||
|
ARCA biopharma
ABIO
|
-60.6 M | - | 1052.0 % | $ 415 M | ||
|
Acasti Pharma
ACST
|
-27.4 M | - | 4.01 % | $ 150 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
-119 M | - | -15.15 % | $ 60.3 M | ||
|
BioXcel Therapeutics
BTAI
|
73 M | $ 1.97 | -1.5 % | $ 4.99 M | ||
|
BioNTech SE
BNTX
|
-973 M | $ 100.02 | 1.18 % | $ 27.2 B | ||
|
AVROBIO
AVRO
|
-76.6 M | - | 1083.1 % | $ 745 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
469 M | $ 27.76 | 0.05 % | $ 1.34 B | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-3.5 M | $ 4.2 | -2.33 % | $ 9.14 B | ||
|
Catalyst Biosciences
CBIO
|
-33.1 M | $ 10.82 | -1.37 % | $ 712 M | ||
|
CureVac N.V.
CVAC
|
-783 M | - | - | $ 867 M | ||
|
Acer Therapeutics
ACER
|
-2.08 M | - | 2.71 % | $ 14 M | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
455 M | $ 11.15 | -1.85 % | $ 721 M | ||
|
BioDelivery Sciences International
BDSI
|
-33.1 M | - | -4.8 % | $ 255 M | ||
|
Axon Enterprise
AXON
|
-404 M | $ 631.42 | 3.01 % | $ 47.8 B | ||
|
Ayala Pharmaceuticals
AYLA
|
-657 K | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
-19.9 M | $ 2.65 | -0.38 % | $ 16.6 M | ||
|
BeiGene, Ltd.
BGNE
|
-2.44 B | - | 0.49 % | $ 251 B | ||
|
AstraZeneca PLC
AZN
|
9.86 B | $ 94.84 | 0.88 % | $ 96.9 B | ||
|
Bellicum Pharmaceuticals
BLCM
|
-34.7 M | - | -9.72 % | $ 5.89 M | ||
|
Acorda Therapeutics
ACOR
|
114 M | - | -24.86 % | $ 820 K | ||
|
Brickell Biotech
BBI
|
-29.7 M | - | -5.38 % | $ 6.06 M | ||
|
Burford Capital Limited
BUR
|
-135 M | $ 9.4 | 1.46 % | $ 1.52 B |